 in precision medicine, has announced the acquisition of Paige, an organization specializing in AI applications for digital pathology.){kind=link}
Tempus AI, a company focused on applying artificial intelligence (AI) in precision medicine, has announced the acquisition of Paige, an organization specializing in AI applications for digital pathology.
Founded in 2017, Paige has developed multiple AI tools for pathology, including the first U.S. Food and Drug Administration (FDA)-cleared AI-based application in this domain. Its technologies have been trained on a dataset comprising nearly 7 million digitized pathology slides paired with clinical and molecular annotations, de-identified to maintain patient privacy. This dataset spans 45 countries and includes diverse demographic representations. Paige has also created what it describes as the first large-scale foundation model for cancer, trained on over one million pathology slides, with applications in cancer detection, biomarker discovery, and preclinical drug development.
According to Tempus, the acquisition provides access to Paige’s dataset, technical expertise, and infrastructure, potentially enabling the development of large-scale foundation models for oncology. Tempus indicated that Paige’s collaboration with Memorial Sloan Kettering Cancer Center has facilitated the creation of one of the most extensive digital pathology resources currently available.